Novelion Reports Second Quarter 2017 Financial Results

Published: Aug 08, 2017

VANCOUVER, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing innovative new therapies for individuals living with rare and unmet need diseases (“Novelion” or the “Company”), today reported financial results for the second quarter ended June 30, 2017 and provided an overview of recent business highlights, including an update on its clinical development programs for metreleptin.

Back to news